Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.45 |
| ▸ | PARP1 | P09874 | 10/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751548 | 0.84 | TRPV1 (0.62) | TRPV1PARP1 | |
| SCHEMBL3756316 | 0.67 | PARP1 (0.46) | TRPV1PARP1TNKSTNKS2 | |
| SCHEMBL619619 | 0.67 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL620269 | 0.67 | TRPV1 (0.43) | TRPV1 | |
| SCHEMBL620480 | 0.66 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL620529 | 0.65 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL4786503 | 0.65 | TRPV1 (0.66) | TRPV1 | |
| SCHEMBL620565 | 0.63 | TRPV1 (0.65) | TRPV1 | |
| SCHEMBL616146 | 0.63 | TRPV1 (0.76) | TRPV1 | |
| SCHEMBL15446074 | 0.63 | TRPV1 (0.76) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20110021549-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | TRPV1 1/4885PARP1 3878/4885TNKS 2631/4885 |
| US-20110021549-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | TRPV1 1/4885PARP1 3878/4885TNKS 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.